Senti Biosciences, Inc.
NASDAQ Global MarketTotal Valuation
Senti Biosciences, Inc. carries a market capitalization of 7.05M, placing it among publicly traded companies globally. Its enterprise value stands at 48.02M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 7.05M |
| Enterprise Value | 48.02M |
Share Statistics
Senti Biosciences, Inc. currently has 31.14M shares outstanding.
| Shares Outstanding | 31.14M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 578.62, and the price-to-book ratio stands at -10.07.
| PE Ratio | N/A |
| PS Ratio | 578.62 |
| PB Ratio | -10.07 |
| P/TBV Ratio | -10.07 |
| P/FCF Ratio | -0.84 |
| P/OCF Ratio | -0.84 |
Enterprise Valuation
| EV / Sales | 873.13 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Senti Biosciences, Inc. maintains a current ratio of 0.83, meaning it holds 0.8x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 0.83 |
| Quick Ratio | 0.45 |
| Debt / Equity | -594.71 |
| Debt / EBITDA | -0.38 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -1,043.00 |
| Return on Assets (ROA) | -97.52 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Senti Biosciences, Inc.'s stock has declined approximately -89.42523% over the past 52 weeks. The 50-day moving average sits at 0.34, while the 200-day moving average is 0.77.
| Beta (5Y) | N/A |
| 52-Week Price Change | -89.42523% |
| 50-Day Moving Average | 0.34 |
| 200-Day Moving Average | 0.77 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Senti Biosciences, Inc. generated 55,000.00 in revenue and converted that into -49.56M in net income, yielding earnings per share of -1.71. EBITDA reached -53.37M, while operating income came in at -56.52M.
| Revenue | 55,000.00 |
| Gross Profit | N/A |
| Operating Income | -56.52M |
| Pretax Income | -49.56M |
| Net Income | -49.56M |
| EBITDA | -53.37M |
| EBIT | -56.52M |
| Earnings Per Share (EPS) | -1.71 |
Balance Sheet
Senti Biosciences, Inc. holds 6.46M in cash and equivalents against 20.23M in total debt, resulting in a net debt position of -2.47M. Total book value stands at -3.40M, with working capital of -2.76M providing operational flexibility.
| Cash & Cash Equivalents | 6.46M |
| Total Debt | 20.23M |
| Net Debt | -2.47M |
| Equity (Book Value) | -3.40M |
| Book Value Per Share | -0.11 |
| Working Capital | -2.76M |
Cash Flow
Senti Biosciences, Inc. produced -38.05M in operating cash flow over the past twelve months.
| Operating Cash Flow | -38.05M |
| Capital Expenditures | N/A |
| Free Cash Flow | -38.05M |
| FCF Per Share | -1.32 |
Margins
Senti Biosciences, Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -102,761.82 and net profit margin of -90,116.36 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -102,761.82 |
| Pretax Margin | -90,116.36 |
| Profit Margin | -90,116.36 |
| EBITDA Margin | -97,030.91 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -60.48 |
| FCF Yield | -119.57 |
Stock Splits
Senti Biosciences, Inc.'s most recent stock split took place on July 18, 2024 with a 10:1 split ratio.
| Last Split Date | 7/18/2024 |
| Split Ratio | 10:1 |
Scores
Senti Biosciences, Inc. posts an Altman Z-Score of -21.05, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -21.05 |